Is Derm Defensive?: Commercial Successes, Current & Upcoming Launches

Thank you to all who joined Cantor’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference. Our expert panelists shared key insights, discussed the challenges facing the landscape, and shared predictions for the next wave of the ever-changing industry.

Our first panel, “Is Derm Defensive?: Commercial Successes, Current & Upcoming Launches” featured David Moatazedi, President & CEO of Evolus, Claude Maraoui, President & CEO of Journey Medical Corporation, Richard Pulik, CFO of Roivant Sciences, and Brian Markison, Chairman of the Board and CEO of RVL Pharmaceuticals. The panel was moderated by Cantor’s Louise Chen.

• Evolus discussed how its growth is robust and that it is taking share despite macro headwinds
• Journey Medical continues to expand its leadership as one of the few standalone medical dermatology companies
• Roivant is hitting on all cylinders, the launch of Vtama is going strong, and its pipeline is advancing
• RVL highlighted that Upneeq continues to gain traction and the product addresses a large unmet need in the market

#Cantor #Cantorfitzgerald #Cantorhealthcare #Cantorconferenceseries #Dermatology #Opthalmology #Medtech #Diagnostic